CITIC SEC maintains a "buy" rating on EB ENVIRONMENT (00257) with a target price of HK$4.1.
Guangda Environment has the potential for high-quality dividend targets. Assuming that the mid-term dividend payout ratio is sustainable, the company's dividend payout ratio will rise to 42% in 2024.
CITIC SEC released a research report stating that they have maintained a "buy" rating for EB ENVIRONMENT (00257), but have lowered the forecasted EPS for 2024 to 0.52/0.61/0.64 Hong Kong dollars (previously forecasted at 0.68/0.69/0.71 Hong Kong dollars). The target price is set at 4.1 Hong Kong dollars.
The subsidiary company CEB GREENTECH (01257), with a 69.70% stake held by the company, announced that they expect a 66-69% increase in net loss for 2024, due to the continuous intense competition in the hazardous waste industry. This is expected to negatively impact the company's performance in 2024. However, the company's revenue structure continues to improve, and cash flow remains in a positive trend. The company has potential as a high-quality dividend target, assuming that the mid-term dividend payout can be sustained, with the dividend payout ratio expected to increase to 42% in 2024.
Related Articles

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families

Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families

Hims & Hers Health (HIMS.US) launches cheap weight loss pills, FDA stops sales the next day, stock price plummets after hours.






